Abstract：
Glaucoma is the leading cause of irreversible blindness worldwide. Schlemm\'s canal surgery using an iTrack flexible microcatheter has become popular because of its high quality-of-life issues and the growing demand for less invasive but effective procedures. The unique design of the microcatheter makes it a multimodal tool, which can be used not only in the field of antiglaucoma surgery but also as a drug delivery system to treat various conditions.
This review presents an update on the selected aspects of a drug delivery system using the iTrack microcatheter, including glaucoma gene therapy and posterior-segment diseases, both in animal models and human patients. The authors also report the case of a patient with branch retinal vein occlusion treated with suprachoroidal bevacizumab in the submacular region administered with the iTrack catheter.
The findings presented in this study may indicate that the application of a microcatheter in open-angle glaucoma gene therapy is reasonable and can be combined with full or partial surgical canaloplasty procedures. Translation of this potential into a treatment modality would require overcoming multiple barriers.
This review presents an update on the selected aspects of a drug delivery system using the iTrack microcatheter, including glaucoma gene therapy and posterior-segment diseases, both in animal models and human patients. The authors also report the case of a patient with branch retinal vein occlusion treated with suprachoroidal bevacizumab in the submacular region administered with the iTrack catheter.
The findings presented in this study may indicate that the application of a microcatheter in open-angle glaucoma gene therapy is reasonable and can be combined with full or partial surgical canaloplasty procedures. Translation of this potential into a treatment modality would require overcoming multiple barriers.
摘要：
■青光眼是全球不可逆失明的主要原因。使用iTrack柔性微导管的Schlemm管道手术已变得流行，因为其高质量的生活问题以及对侵入性较小但有效的手术的需求不断增长。微导管的独特设计使其成为多模态工具，它不仅可以用于抗青光眼手术领域，还可以作为药物递送系统来治疗各种疾病。
■这篇综述介绍了使用iTrack微导管的药物递送系统的选定方面的更新，包括动物模型和人类患者的青光眼基因治疗和后段疾病。作者还报道了一例视网膜分支静脉阻塞患者在黄斑下区域用脉络膜上贝伐单抗治疗的病例。
■这项研究的发现可能表明，微导管在开角型青光眼基因治疗中的应用是合理的，可以与完全或部分手术泪管成形术相结合。将这种潜力转化为治疗方式需要克服多种障碍。
■这篇综述介绍了使用iTrack微导管的药物递送系统的选定方面的更新，包括动物模型和人类患者的青光眼基因治疗和后段疾病。作者还报道了一例视网膜分支静脉阻塞患者在黄斑下区域用脉络膜上贝伐单抗治疗的病例。
■这项研究的发现可能表明，微导管在开角型青光眼基因治疗中的应用是合理的，可以与完全或部分手术泪管成形术相结合。将这种潜力转化为治疗方式需要克服多种障碍。
